Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interleukin-1 (IL-1) and Interferon Gamma (IFNg) Inhibition During COVID 19 Inflammation: Randomized, Controlled Study Assessing Efficacy and Safety of Anakinra and Ruxolitinib

NCT04366232 is registered in ClinicalTrials.gov with Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer as lead sponsor.

NCT NCT04366232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04366232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interleukin-1 (IL-1) and Interferon Gamma (IFNg) Inhibition During COVID 19 Inflammation: Randomized, Controlled Study Assessing Efficacy and Safety of Anakinra and Ruxolitinib
Lead sponsor
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Phase
Phase 2
Overall status
Terminated
Start date
August 19, 2020
Completion date
October 2, 2020
Enrollment
2 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19